Neurexin 1 (NRXN1) Human shRNA Plasmid Kit (Locus ID 9378)

CAT#: TL302885

NRXN1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector

Specifications

Product Data

• Locus ID: 9378
• Synonyms: Hs.22998; PTHSL2; SCZD17
• Vector: pGFP-C-shLenti
• Format: Lentiviral plasmids
• Kit Components: NRXN1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 9378). 5µg purified plasmid DNA per construct
  Non-effective 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
• RefSeq: NM_001135659, NM_001320156, NM_001320157, NM_001330077, NM_001330078, NM_001330079, NM_001330081, NM_001330082, NM_001330083, NM_001330084, NM_001330085, NM_001330086, NM_001330087, NM_001330088, NM_001330089, NM_001330090, NM_001330091, NM_001330092, NM_001330093, NM_001330094, NM_001330095, NM_001330096, NM_001330097, NM_004801, NM_138735, BC046631, BC125179, BC125180, BC150247, BM021375
• Summary: This gene encodes a single-pass type I membrane protein that belongs to the neurexin family. Neurexins are cell-surface receptors that bind neuroligins to form Ca(2+)-dependent neurexin/neuroligin complexes at synapses in the central nervous system. This complex is required for efficient neurotransmission and is involved in the formation of synaptic contacts. Three members of this gene family have been studied in detail and are estimated to generate over 3,000 variants through the use of two alternative promoters (alpha and beta) and extensive alternative splicing in each family member. Recently, a third promoter (gamma) was identified for this gene in the 3' region. Mutations in this gene are associated with Pitt-Hopkins-like syndrome-2 and may contribute to susceptibility to schizophrenia. [provided by RefSeq, Aug 2016]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, align it with our published shRNA design sequences. If these do not align, please utilize our custom shRNA service
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).